

Can we have it "whole"?

From Value Flowers, to HEMA and Whole Health.

Prof. Lotte Steuten, PhD Deputy Chief Executive Office of Health Economics London, UK




Conflict of Interest Statement

- Lotte Steuten is an employee of the Office of Health Economics, a registered charity and Independent Research Organisation in the UK, which receives funding from a variety of public and private sector sources on a broad range of topics relevant to the economics of health.
- The opinions and ideas presented here are my own based on 20+ years of experience in HEOR and HTA globally, and do not necessarily reflect those of OHE or any of the organisations it receives funding from.


ISPOR Value Flower helps to conceptualise broader benefits

- The first concept of the value flower originates from a <u>2016</u>
 <u>OHE white paper</u>¹
- Brought to fame by an ISPOR Special Task Force to address limitations of traditional cost-effectiveness analysis (CEA) from a payer perspective
- Various versions exist but usually around **12 value elements**
 - 2 '**core**' elements of value
 - 2 '**common but inconsistently used**' elements
 - 8 'novel' broader value elements
- Further expanded for example with the GCEA approach, including ways to measure each value element (Shafrin et al., 2024)

¹ Garrison L, Mestre-Ferrandiz J, Zamora B. (2016) The Value of Knowing and Knowing the Value: Improving the Health Technology Assessment of Complementary Diagnostics. OHE Whitepaper. Available from https://www.ohe.org/publications/value-knowing-and-knowingvalue-improving-health-technology-assessment-complementary/



Is the value flower already blossoming?



Source: Breslau, R. M., Cohen, J. T., Diaz, J., Malcolm, B., & Neumann, P. J. (2023). A review of HTA guidelines on societal and novel value elements. *International journal of technology assessment in health care*, 39(1), e31.

OHE

Three **good** reasons to consider broader benefits in HTA

- It better reflects societal preferences (whole health?)
- It can reduce systematic over- or undervaluation of interventions
- It can support better resource allocation across sectors

Three **not so good/naive** reasons to consider broader benefits in HTA

- It makes all interventions look more cost-effective
- It helps get more positive HTA decisions
- Other countries/agencies are doing it

The good, the bad, the ugly? (it's context dependent!)



Three reasons to **not** consider broader benefits in HTA

- Alignment with governance and mandate
- Methodologically more straightforward
- Avoids (some) difficult trade-offs






What's in a name?

- **HEMA** (Dutch pronunciation: ['fie:ma:]; originally an acronym for *Hollandsche Eenheidsprijzen Maatschappij Amsterdam*, "Standard Prices Company of Holland, Amsterdam"), is a Dutch variety chain store.
- "Known for balancing high quality, great design, and affordable prices, HEMA represents a model of holistic value."
- "Broader benefits" first topic of HEMA: Health Economics Methods Advisory
 Group. Deliverable will be a paper describing:
 - HTA context setting
 - Classification of value elements
 - Principles for the inclusion of additional value elements
 - Potentially, impact case studies

Whole health, whole impact?





Thank you



Prof. Lotte Steuten, PhD Deputy Chief Executive Isteuten@ohe.org

We are rebranding

Want in on the secret?

Be the first to see the full reveal - sign up to our newsletter now.





Visit our website at ohe.org

